Cosmo Signs a Distribution and License Agreement with Glenmark for Winlevi in Europe and South Africa
- Cassiopea will receive $5M up front & is eligible to receive regulatory & sales milestones along with royalties on net sales. Glenmark will lead the registration of the product in South Africa & the UK while Cosmo will be the exclusive supplier of the product
- Glenmark will get an exclusive right from Cassiopea, a subsidiary of Cosmo to commercialize Winlevi in 15 EU countries (Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain & Sweden) as well as in South Africa & the UK
- Cassiopea will be responsible for the Centralized Marketing Authorization at EMA. Winlevi was approved in the US as a novel drug for the topical treatment of acne in patients aged ≥12yrs.
Ref: PR Newswire | Image: Cosmo
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.